States that do provide coverage have tried to manage costs by putting prescribing limits on the GLP-1s. There’s also some evidence that if Medicaid patients lose weight with the drugs, they’ll be healthier and less expensive to cover, said Tracy Zvenyach of Obesity Action, an advocacy group that urges states to provide coverage.

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

Studies show that GLP-1 agonists can help patients lose 5-15% of their body weight when combined with diet and exercise. Mounjaro (Terzepatide) is a dual GLP-1/GIP (Gastric Inhibitory Peptide) receptor agonist,